These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 36871574)

  • 1. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
    J Crohns Colitis; 2024 Aug; 18(8):1270-1282. PubMed ID: 38613425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials.
    Takeuchi K; Hisamatsu T; Nakase H; Matsuoka K; Keating M; Yuasa H; Oe M; Arai S; Mazur R; Hibi T
    Digestion; 2024 Sep; ():1-9. PubMed ID: 39317165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
    Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG
    J Crohns Colitis; 2024 Nov; 18(11):1780-1794. PubMed ID: 38877972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
    Magro F; Peyrin-Biroulet L; Sands BE; Danese S; Jairath V; Goetsch M; Bhattacharjee A; Wu J; Branquinho D; Modesto I; Feagan BG
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39089519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
    Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
    J Crohns Colitis; 2024 Oct; 18(10):1596-1605. PubMed ID: 38700040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in UC: Analyses of the ELEVATE UC Clinical Programme.
    Sands BE; Leung Y; Rubin DT; Gecse KB; Panés J; Goetsch M; Wang W; Woolcott JC; Smith CC; Wosik K; Schreiber S
    J Crohns Colitis; 2024 Sep; ():. PubMed ID: 39306680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Vermeire S; Sands BE; Tilg H; Tulassay Z; Kempinski R; Danese S; Bunganič I; Nitcheu J; Santo J; Scherrer D; Biguenet S; Ehrlich HJ; Steens JM; Gineste P; Sandborn WJ
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1024-1035. PubMed ID: 36075249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.